Physician profile
Jason Winterhalter
NPI 1639127756
$3,516.21
in general payments reported to CMS, 2019-2025
32 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $503 · 2022: $589 · 2023: $908 · 2024: $518 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $686.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $630.57 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $348.96 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $252.04 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $203.72 | 2019-2022 | |
| Astellas Pharma US INC | $150.89 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $149.96 | 2019-2025 | |
| Amgen INC. | $144.77 | 2019-2022 | |
| Glaxosmithkline, LLC. | $141.31 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $113.45 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $77.24 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.06 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $54.69 | 2019-2023 | Gardasil 9, Vaxneuvance |
| Edwards Lifesciences Corporation | $52.24 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.29 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $44.32 | 2022-2023 | Camzyos |
| Xeris Pharmaceuticals, INC. | $41.30 | 2024-2025 | Gvoke Hypopen |
| Dexcom, INC. | $37.75 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $36.18 | 2022 | |
| Exact Sciences Corporation | $31.85 | 2023 | Cologuard Collection Kit |
| Alphatec Spine, INC | $23.95 | 2023 | Invictus Mis |
| Upsher-Smith Laboratories LLC | $21.25 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.07 | 2023 | |
| Phathom Pharmaceuticals, INC. | $19.20 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $17.53 | 2025 | Rexulti |
| Abbott Laboratories | $15.93 | 2024 | Freestyle Libre 3 |
| Exeltis, USA INC. | $14.76 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.52 | 2023 | Seglentis, Livalo |
| Nestle Healthcare Nutrition INC. | $13.39 | 2023 | |
| Novartis Pharmaceuticals Corporation | $12.50 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Winterhalter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.